|Bid||2.6100 x 1800|
|Ask||2.7900 x 1300|
|Day's Range||2.6500 - 2.9800|
|52 Week Range||1.6000 - 4.1500|
|Beta (3Y Monthly)||2.54|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 14, 2019 - Oct 18, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.25|
It hasn't been the best quarter for Biomerica, Inc. (NASDAQ:BMRA) shareholders, since the share price has fallen 11...
MaxHealth to distribute Biomerica’s colorectal screening test to help identify the early warning signs of colorectal cancer. IRVINE, Calif., June 05, 2019 (GLOBE NEWSWIRE) -- Biomerica, Inc. (BMRA) announced it has signed an exclusive sales and distribution agreement with MaxHealth for the sale of its EZ Detect product in China. The agreement requires MaxHealth to meet annual minimum purchase requirements, which in aggregate, equal $17 million over the initial seven year term and further requires an upfront pre-payment of $1 million after meeting certain conditions.
The big shareholder groups in Biomerica, Inc. (NASDAQ:BMRA) have power over the company. Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies...
Biomerica (BMRA) reported financial results for their fiscal 2019 third quarter ending February 28, 2019. Revenue has decreased each of the first three quarters of 2019 as compared to the respective prior-year periods and through the first nine months, is down 9% from 2018. Revenue through the first nine months from each of three most significant territories is down from last year.
Biomerica, Inc. (BMRA) today reported net sales of $4,034,822 for the nine months ending February 28, 2019, compared to $4,433,785 for the period ended February 28, 2018. Sales for the three months ending February 28, 2019 were $1,261,161 compared to $1,375,666 for the period ended February 28, 2018. In addition, the Company announced progress in both its InFoods® IBS clinical study and H. pylori study as well as the issuance of its first patent pertaining to the Company’s InFoods® family of products that are designed to allow for a revolutionary new treatment option for patients suffering from Irritable Bowel Syndrome (IBS) and other gastrointestinal diseases. “We are very pleased that the United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance for Biomerica’s first U.S. patent pertaining to the Company’s InFoods® family of products. The patent validates the unique InFoods product which is designed to allow physicians to offer new and better therapies to patients.
Biomerica, Inc. (BMRA) announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Biomerica’s first U.S. patent pertaining to the Company’s InFoods® family of products that allow for revolutionary new treatment option for patients suffering from Irritable Bowel Syndrome (IBS) and other gastrointestinal diseases. Specifically, this allowed application (#15/526,240) contains numerous claims that broadly cover a product that enables physicians to identify patient specific foods (e.g.
LOS ANGELES, CA / ACCESSWIRE / March 12 , 2019 / LD Micro, a company that puts on conferences for micro-cap and small-cap companies will be hosting 46 companies on March 12th (that's today) and 13th, starting ...
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! Anyone researching Biomerica, Inc. (NASDAQ:BMRA) might want to consider theRead More...
Based on recent discussions between Biomerica and the United States Food and Drug Administration (FDA) regarding the regulatory pathway for final FDA clearance of the Company’s H. pylori product, the Company needs less than 40 clinical trial patient samples in addition to the 210 samples already collected. These final clinical patient samples are expected to be collected over the next few months, after which the Company will complete the remaining analytical and clinical agreement studies and prepare a submission to the FDA for 510(k) FDA clearance. Helicobacter pylori (H. pylori) infection is one of the most common, chronic, bacterial infections affecting humans. Complications associated with H. pylori infections include ulcers, inflammation of the stomach lining and stomach cancer. The diagnosis of H. pylori is important given that specific antibiotic treatment is highly effective in improving outcomes.
How far off is Biomerica, Inc. (NASDAQ:BMRA) from its intrinsic value? Using the most recent financial data, I am going to take a look at whether the stock is fairly Read More...
Results of an n=97 randomized, investigator-blinded food-exclusion study showed that Biomerica’s (BMRA) first-generation ELISA immunoglobulin G (IgG) antibody assay was able to significantly reduce ulcerative colitis symptoms and improve participants’ quality of life. In addition, this study assessed BMRA’s test in individuals with ulcerative colitis (UC) – while InFoods has been developed primarily to determine optimal food exclusion diets for people with irritable bowel syndrome.
Biomerica, Inc. (BMRA) today reported net sales of $1,500,791 for the three months ended November 30, 2018, compared to $1,613,636 for the same period in the previous year. Net sales were $2,773,661 for the six months ended November 30, 2018 compared to $3,058,119 for the same period in last year. The Company ended the quarter with approximately $798,000 in backlog for open orders, which were not shipped as of November 30, 2018. Biomerica announced a net loss for the three months ended November 30, 2018 of $477,244, or $0.05 per share, versus a net loss of $268,661, or $0.03 per share, in the previous fiscal year during the same quarter. The net loss for the six months ended November 30, 2018 was $928,984, or $0.10 per share, compared to net loss of $475,720, or $0.06 per share in the prior fiscal year.
Biomerica, Inc. (BMRA) announced that is has signed a three year agreement with Medline Industries for the distribution of Biomerica’s EZ Detect™ colorectal disease screening test designed to help identify an early warning sign of colorectal cancer. The EZ Detect colorectal screening test is the simplest at home test to detect fecal occult (hidden) blood, an early warning sign of colorectal cancer. With over 18,000 employees worldwide, 1,600 direct sales reps and $10.2 billion in sales, Medline Industries is ranked 32 on the Forbes list of largest private companies. Medline is the largest privately held manufacturer and distributor of medical supplies uniquely positioned to provide products, education and support across the continuum of care (from large healthcare systems and independent physician practices to home health patients and their families).
NEW YORK, Nov. 16, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Every investor in Biomerica Inc (NASDAQ:BMRA) should be aware of the most powerful shareholder groups. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to Read More...
Eliminating positive foods identified by Biomerica’s diagnostic product showed statistically significant improvements (p
Biomerica (BMRA) reported financial results for their fiscal 2019 first quarter ending August 31, 2018. The weakness related almost entirely to Europe and the U.S., which were both down double-digit percentages from the year-earlier period. Fortunately Asia, which accounts for ~50% of total revenue saw solid gains from both comparable periods, limiting the yoy total revenue slide and pushing it into positive territory sequentially.
Zero-debt allows substantial financial flexibility, especially for small-cap companies like Biomerica Inc (NASDAQ:BMRA), as the company does not have to adhere to strict debt covenants. However, it also faces higher Read More...
Biomerica (BMRA) reported financial results for their fiscal 2018 fourth quarter ending May 31, 2018. While our model had revenue inching up 6% for the full-year reflecting an expectation that rebounding sales in Asia would more than offset ongoing softness in both Europe and the U.S., that was far from the case. Instead, the nearly across-the-board (Latin America was the sole bright spot) weakness in Q4, which most notably included a 42% yoy contraction in Asia, resulted in annual sales falling almost 4%.